Cerebrolysin
Porcine-brain-derived peptide complex used in stroke, traumatic brain injury, and dementia in many countries outside the US.
At a glance
What it is: Porcine-brain-derived peptide complex used in stroke, traumatic brain injury, and dementia in many countries outside the US..
Primary research applications:
- Acute ischemic stroke (adjunct, several countries)
- Traumatic brain injury
- Vascular and Alzheimer's dementia
Editorial summary: Cerebrolysin is one of the few neuroactive peptide preparations with a multi-decade clinical track record outside the US — used routinely in many countries for stroke, brain injury, and dementia. Its evidence base is genuinely substantial in absolute terms but methodologically heterogeneous, and Cochrane reviews have repeatedly flagged risk-of-bias concerns alongside positive signals.
- Class / structure
- Mixture of low-molecular-weight peptides and free amino acids derived from porcine brain protein hydrolysate
- Half-life
- Mixture; component-specific
- First described
- 1970s
- Regulatory status
- Not FDA-approved; approved in 50+ countries including Russia, China, Mexico, Austria
What is Cerebrolysin?
Cerebrolysin is a parenteral peptide-amino-acid mixture intended to mimic neurotrophic factor activity. It is used as adjunct therapy in stroke, traumatic brain injury, and various dementias in countries where it is approved.
Discovery and development
Cerebrolysin was developed by Ever Pharma (originally Ebewe Pharma) in Austria in the 1970s. It is produced by enzymatic breakdown of purified porcine brain proteins, yielding a defined mixture of low-molecular-weight neuropeptides (~15%) and free amino acids (~85%). Despite its complexity as a mixture, it has been studied in dozens of randomized trials across several decades.
Mechanism of action
Mechanistic studies suggest cerebrolysin acts through multiple pathways: neurotrophic factor mimicry (resembling BDNF, GDNF, NGF), modulation of glutamate-mediated excitotoxicity, and effects on endogenous protein clearance pathways. It is one of the few peptide preparations specifically claimed to be neurotrophic in the broad sense.[1]
Pharmacokinetics
Pharmacokinetic data is necessarily complex given the mixture nature of the preparation. Active components are believed to cross the blood-brain barrier and act on multiple central nervous system pathways including BDNF/CREB signaling.
What the research shows
The peer-reviewed literature on Cerebrolysin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Improves outcomes in acute ischemic stroke | Mixed — positive trials and meta-analyses; Cochrane skeptical | Mixed |
| Improves outcomes in TBI | CAPTAIN trials supportive | Promising |
| Has neurotrophic factor-like activity in vivo | Multiple mechanistic studies | Promising |
| FDA-approved in the US | Not approved; used outside the US | Unsupported |
Reported user experiences
How the research describes administration
Cerebrolysin is given intravenously or intramuscularly in courses of typically 10–30 daily injections, often repeated periodically. Administration is by clinicians in countries where it is approved.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Cerebrolysin sits in an unusual epistemic position: more clinical experience than almost any other neuroactive peptide preparation, but methodological inconsistency that prevents the field from declaring victory. For readers exploring this space, the appropriate stance is genuine curiosity tempered by recognition that the mixture-based pharmacology and risk-of-bias concerns in many trials make confident efficacy claims difficult.
Frequently asked questions
Is cerebrolysin available in the United States?
It is not FDA-approved. Some patients access it through international compounding pharmacies or by traveling abroad. This is outside the US regulatory framework.
Is cerebrolysin a single peptide?
No. It is a mixture of low-molecular-weight peptides and free amino acids produced by enzymatic hydrolysis of porcine brain protein. This complicates traditional pharmacology but is also what gives it its broad mechanism.
References
- Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009;26(11):893-915. https://pubmed.ncbi.nlm.nih.gov/19848437/
- Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke. 2012;43(3):630-636. https://pubmed.ncbi.nlm.nih.gov/22282884/
- Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2020;7(7):CD007026. https://pubmed.ncbi.nlm.nih.gov/32662068/